Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • About
    • General information
    • Staff
    • Editorial board
    • Open access
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ Open
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN
CMAJ Open

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • About
    • General information
    • Staff
    • Editorial board
    • Open access
    • Contact
  • RSS feeds
Research
Open Access

The success of publicly funded rotavirus vaccine programs for preventing community- and hospital-acquired rotavirus infections in Canadian pediatric hospitals: an observational study

Nicole Le Saux, Julie Bettinger, Hennady P. Shulha, Manish Sadarangani, Doug Coyle, Timothy F. Booth, Taj Jadavji, Scott A. Halperin and For members of Immunization Monitoring Program Active
December 19, 2023 11 (6) E1156-E1163; DOI: https://doi.org/10.9778/cmajo.20220245
Nicole Le Saux
Children’s Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children’s Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children’s Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Bettinger
Children’s Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children’s Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children’s Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hennady P. Shulha
Children’s Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children’s Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children’s Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manish Sadarangani
Children’s Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children’s Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children’s Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS
BM BCh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doug Coyle
Children’s Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children’s Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children’s Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy F. Booth
Children’s Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children’s Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children’s Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taj Jadavji
Children’s Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children’s Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children’s Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott A. Halperin
Children’s Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children’s Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children’s Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Children’s Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children’s Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children’s Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1:

    (A) Average yearly rate of community-acquired rotavirus admissions per 10 000 hospital admissions and (B) average yearly rate of hospital-acquired rotavirus infections per 1000 patient-days by province from 2005 to 2020, in the pre- and post-vaccine periods, excluding year of program implementation (year 0).

  • Figure 2:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2:

    (A) Average yearly rate of community-acquired rotavirus admissions per 10 000 hospital admissions and (B) average yearly rate of hospital-acquired rotavirus infections per 1000 patient-days by age group from 2005 to 2020, in the pre- and post-vaccine periods, excluding year of program implementation (year 0).

Tables

  • Figures
    • View popup
    Table 1:

    Dates of introduction for publicly funded rotavirus immunization programs in Canada by province with and without IMPACT sites

    Province or territoryDateDesignated year 0
    With IMPACT sites
    Ontario (2 sites: Hospital for Sick Children, Toronto, and Children’s Hospital of Eastern Ontario, Ottawa)August 20112011
    Québec (3 sites: CHU Sainte-Justine, Montréal; Montréal Children’s Hospital, Montréal; and CHU Laval–Centre mère-enfant Soleil, Québec)November 20112012
    British Columbia (1 site: BC Children’s Hospital)January 20122012
    Saskatchewan (1 site: Jim Pattison Children’s Hospital, Saskatoon)November 20122013
    Manitoba (1 site: The Children’s Hospital of Winnipeg, Winnipeg)April 20142014
    Alberta (2 sites: Stollery Children’s Hospital, Edmonton, and Alberta Children’s Hospital, Calgary)June 20152015
    Newfoundland (1 site: Eastern Health Janeway Child Health and Rehabilitation Centre, St. John’s)September 20152015
    Nova Scotia (1 site: IWK Health Centre, Halifax)November 20192020
    Without IMPACT sites
    Prince Edward IslandDecember 2010NA
    New BrunswickMay 2018NA
    Northwest TerritoriesFall 2013NA
    NunavutDecember 2017NA
    YukonOctober 2012NA
    • Note: CHU = centre hospitalier universitaire; IMPACT = Immunization Monitoring Program, Active; NA = not applicable.

    • View popup
    Table 2:

    Ages of patients with community-acquired rotavirus infections admitted to hospital or hospital-acquired rotavirus infection in the pre-vaccine versus post-vaccine time periods*

    AgeNo. (%) of patients in pre-vaccine program period†No. (%) of patients in post-vaccine program period†
    Communityacquired
    n = 3331
    Hospitalacquired
    n = 1109
    Total
    n = 4440
    Communityacquired
    n = 656
    Hospitalacquired
    n = 162
    Total
    n = 818
    Age, yr, mean2.32.02.23.42.83.0
    Age, yr, median (IQR)1.5 (0.8–2.7)0.8 (0.3–1.8)1.3 (0.6–2.5)2.4 (1.1–4.9)1.0 (0.2–3.4)1.8 (0.8–3.8)
    Age group
     0–11 mo1118 (33.5)648 (58.4)1766 (39.8)161 (24.6)79 (48.8)240 (29.3)
     12–23 mo1027 (30.8)209 (18.8)1236 (27.8)129 (19.7)26 (16.0)155 (19)
     24–59 mo833 (25.0)133 (12.0)966 (21.8)207 (31.6)27 (16.7)234 (28.6)
     5–9 yr243 (7.3)56 (5.0)299 (6.7)126 (19.2)15 (9.2)141 (17.2)
     10–16 yr110 (3.3)63 (5.7)173 (3.9)33 (5.0)15 (9.2)48 (5.9)
    • Note: IQR = interquartile range.

    • ↵* Excludes 433 patients from year of vaccine introduction (year 0) at all sites.

    • ↵† Unless indicated otherwise.

    • View popup
    Table 3:

    Comparison of clinical presentations and hospital admission for patients with community-acquired rotavirus infections (2008–2020) in the pre-vaccine and post-vaccine periods, excluding those from year of vaccine implementation (year 0)

    CharacteristicNo. (%) of patients
    Pre-vaccine period
    n = 1972
    Post-vaccine period
    n = 656
    Clinical presentations
     Diarrhea, vomiting and fever1466 (74)408 (62)
     Dehydration1594 (81)509 (78)
     Electrolyte abnormalities920 (47)282 (43)
     Shock†37 (2)20 (3)
     Seizures145 (7)54 (8)
     IV hydration1906 (97)624 (95)
    Hospital admission
     ICU admission75 (3.8)38 (5.7)
      Days in ICU, median (IQR)2 (1–4)1 (1–3)
     Length of hospital stay, d, median (IQR)2 (2–4)3 (2–5)
    • Note: ICU = intensive care unit, IQR = interquartile range, IV = intravenous.

    • * Unless otherwise indicated.

    • ↵† Shock criteria included low blood pressure and tachycardia.

    • View popup
    Table 4:

    Average rates of hospital admission for community-acquired rotavirus infection and hospital-acquired rotavirus infection among age groups that were not eligible for the vaccine in the pre- and post-vaccine periods

    VariableRateAverage decrease in rate, %
    Pre-vaccine periodPost-vaccine period
    Average admission rate for community-acquired infections per 10 000 hospital admissions
    Age group
     24–59 mo15.41.491
     5–9 yr6.11.674
     10–16 yr2.30.576
    Average rate of hospital-acquired infections per 1000 patient-days
    Age group
     24–59 mo0.0540.00395
     5–9 yr0.0220.00385
     10–16 yr0.0120.00561
PreviousNext
Back to top

In this issue

CMAJ Open: 11 (6)
Vol. 11, Issue 6
1 Nov 2023
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ Open.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The success of publicly funded rotavirus vaccine programs for preventing community- and hospital-acquired rotavirus infections in Canadian pediatric hospitals: an observational study
(Your Name) has sent you a message from CMAJ Open
(Your Name) thought you would like to see the CMAJ Open web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The success of publicly funded rotavirus vaccine programs for preventing community- and hospital-acquired rotavirus infections in Canadian pediatric hospitals: an observational study
Nicole Le Saux, Julie Bettinger, Hennady P. Shulha, Manish Sadarangani, Doug Coyle, Timothy F. Booth, Taj Jadavji, Scott A. Halperin, For members of Immunization Monitoring Program Active
Nov 2023, 11 (6) E1156-E1163; DOI: 10.9778/cmajo.20220245

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The success of publicly funded rotavirus vaccine programs for preventing community- and hospital-acquired rotavirus infections in Canadian pediatric hospitals: an observational study
Nicole Le Saux, Julie Bettinger, Hennady P. Shulha, Manish Sadarangani, Doug Coyle, Timothy F. Booth, Taj Jadavji, Scott A. Halperin, For members of Immunization Monitoring Program Active
Nov 2023, 11 (6) E1156-E1163; DOI: 10.9778/cmajo.20220245
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Collections

  • Clinical
    • Pediatrics
      • Adolescents
      • Children
      • Infants
      • Neonates
    • Gastroenterology
      • Infection
    • Infectious Diseases
      • Other infectious diseases
    • Public Health
      • Vaccination

Content

  • Current issue
  • Past issues
  • Collections

About

  • General Information
  • Staff
  • Editorial Board
  • Advisory Panel
  • Contact Us
  • Reprints
  • Copyright and Permissions
CMAJ Group

Copyright 2025, CMA Impact Inc. or its licensors. All rights reserved. ISSN 2291-0026

All editorial matter in CMAJ OPEN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].

CMA Civility, Accessibility, Privacy

 

 

Powered by HighWire